Terry J. Rosen - 07 Mar 2022 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Chief Executive Officer, Director
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
07 Mar 2022
Net transactions value
$0
Form type
4
Filing time
10 Mar 2022, 16:04:54 UTC
Previous filing
20 Dec 2021
Next filing
10 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Gift $0 -321,074 -100% $0.000000* 0 07 Mar 2022 Rosen GRAT No. 2 F1
transaction RCUS Common Stock Award $0 +65,000 +31% $0.000000 276,570 08 Mar 2022 Direct F2
holding RCUS Common Stock 3,433,870 07 Mar 2022 By The Rosen Family Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCUS Stock Option (right to buy) Award $0 +275,000 $0.000000 275,000 08 Mar 2022 Common Stock 275,000 $33.03 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 321,074 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust. The remaining 62,930 shares were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13.
F2 Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2022, subject to the Reporting Person's continued service to the Company.
F3 62,930 shares previously held by the reporting person in Rosen GRAT No. 2 were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13.
F4 The option is exercisable in 48 equal monthly installments after January 1, 2022, subject to the Reporting Person's continued service to the Company.